AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 161 min read$FENC

Brughera Marco Maria sold $160K of FENC

Brughera Marco Maria sold 15,545 shares of FENNEC PHARMACEUTICALS INC. (FENC) at $10.29 ($0.16M total) on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Brughera Marco Maria
Published Sep 16, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$FENC
Neutral
low confidence
Mentioned
$FENC
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FENCNeutralLow
01

Why it matters

The director's complete exit may be noted by investors but is unlikely to move the stock materially.

02

Market read

A routine insider sale with limited trading relevance.

03

What to watch

Potential upcoming dilution or secondary offering that prompted the exit.

Relevance 3/10Novelty 3/10Timing: post‑market 2026‑09‑15

Background

Form 4 filing discloses insider trades; this is the first public report of the director's exit.

Company-level read

Ticker impact

$FENCNeutralLow confidence
Context

Director Brughera Marco Maria sold 15,545 shares for $159,958, leaving a zero holding.

Expected impact

Minor downward pressure, likely within normal volatility.

Evidence & confidence

Sale amount is small relative to market cap; no broader catalyst.

Market effects

Sector

None; the transaction is company‑specific.

Regional

None; limited to the issuer.

Global

None

Counterpoint

What could challenge this read

The sale could be a routine liquidity move, not a negative signal.

Key entities

  • Company
    Fennec Pharmaceuticals Inc.

    Biopharma issuer of ticker FENC.

  • Insider
    Brughera Marco Maria

    Director who sold his entire stake.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

FENC insider trading history →

Related articles

SEP 17
$FENCMedAI 8/10

FENNEC PHARMACEUTICALS INC. (FENC): Other Events

FENNEC PHARMACEUTICALS INC. (FENC) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Fennec Pharmaceuticals Announces ORAL PRESENTATION OF DETAILED Results From Investigator-Initiated Phase 2 STS-J01 Clinical Study of PEDMARK ® in Japan AT SIOP 2026 ​ ~ Primary Endpoint Met: American Speech-Language-Hearing Association (ASHA)-Defined Hearing Loss Occ

SEC EDGAR 8-K2 min
AUG 13
$FENCMed

Adherex Technologies Q2 Earnings Call Highlights

Fennec Pharmaceuticals (NASDAQ:FENC) reported Q2 results on an earnings call. Net product sales were $17.1 million, up 78% year over year. Non-GAAP adjusted EBITDA was $2.8 million versus a $1.2 million loss a year earlier. Cash and cash equivalents were $41.2 million at June 30, 2026. Management cited PEDMARK momentum and no quantitative 2026 revenue outlook.

yahoo.com6 min